55721-31-8
基本信息
沙利诺马辛
沙利霉素钠
盐霉素钠盐
盐霉素预混
盐霉素 单钠盐 水合物
盐霉素SV钠盐的五个半水合物
Salinomycin-Natrium
Salinomycin 1-sodium salt
Salinomycin sodium premix
Salinomycin, monosodium salt
SalinoMycin SodiuM Salt (12% Min.)
SalinoMycin 12% 24% HOUSE STANDARD
salinomycin monosodium salt hydrate
SALINOMYCIN SODIUM SALT 2.5-HYDRATE
Salinomycin hydrate monosodium salt
物理化学性质
| 外观性状 | 白色或淡黄色结晶性粉末，微有特异臭，熔点140-142℃。易溶于丙酮、三氯甲烷、苯、乙酸乙酯、乙醚和甲醇，几乎不溶于水。大白鼠经口LD5070-100mg/kg，小白鼠经口LD5050mg/kg，鸡LD50150mg/kg。 |
| 熔点 | 140-142° |
| 比旋光度 | D25 -37° (c = 1 in ethanol) |
| 储存条件 | APPROX 4°C |
| 溶解度 | 溶于二甲基亚砜。 |
| 形态 | neat |
| 颜色 | 白色 |
| Merck | 13,8415 |
| BRN | 4901827 |
| 稳定性 | DMSO中的溶液可在-20°下稳定储存3个月。 |
安全数据
| 危险性符号(GHS) |  GHS06 |
| 警示词 | 危险 |
| 危险性描述 | H301 |
| 防范说明 | P264-P270-P301+P310-P405-P501 |
| 危险品标志 | T |
| 危险类别码 | 25 |
| 安全说明 | 45 |
| 危险品运输编号 | 2811 |
| WGK Germany | 3 |
| 危险等级 | 6.1 |
| 包装类别 | III |
制备方法
应用领域
常见问题列表
Wnt/β-catenin
Salinomycin (0.1-8 µM) inhibits the growth of HUVECs in a dose-dependent manner, accounting for 32.1 and 59.2% inhibition at 4 and 8 µM, respectively. HUVECs exposed to 2, 4 and 8 µM of Salinomycin for 48 h show a dose-dependent reduction in cell number and a change in cell morphology. Salinomycin (4 µM) treatment effectively inhibits HUVEC migration and invasion, and significantly disrupt the capillary-like tube formation of HUVECs. Salinomycin significantly suppresses the expression levels of phosphorylated (p)-FAK in a time- and dose-dependent manner in HUVECs. Salinomycin inhibits HUVEC angiogenesis by disturbing the VEGF-VEGFR2-AKT signaling axis. Combination of RSVL and Salinomycin synergistically inhibits the proliferation of TNBC (MDA-MB-231) cells. RSVL and Salinomycin effectively reduce wound healing, colony and tumorosphere forming capability in TNBC cells. Synergistic combination of RSVL and Salinomycin induces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2 expression as comparison to untreated and alone drug treatments. Salinomycin (0, 2, 4, 8 and 16 μM) significantly inhibits the proliferation of A2780 and SK-OV-3 cell lines in a dose- and time-dependent manner, (IC 50 24h : 13.8 μM, IC 50 48h : 6.888 μM and IC 50 72h : 4.382 μM for A2780 cell lines), (IC 50 24h : 12.7 μM, IC 50 48h : 9.869 μM and IC 50 72h : 5.022 μM for SK-OV-3 cell lines). Salinomycin blocks the Wnt/β-catenin pathway in EOC cells. Salinomycin (2 μM) reduces cancer cell proliferation, inhibits STAT3 phosphorylation and P38 and β-catenin expressions, and suppresses epithelial-mesenchymal transition in colorectal cancer cells. Salinomycin (1-5 μM) inhibits cancer cell proliferation and STAT3 signaling in colorectal cancer cells. Furthermore, Salinomycin activates Akt (Ser 473) and down-regulates Hsp27 (Ser 82) phosphorylation in HT-29 and SW480. Salinomycin down-regulates hTERT and reduces telomerase activity when combined with telomerase inhibitor.
Salinomycin (5 and 10 mg/kg) significantly supresses the average tumor volume and tumor weight. Salinomycin hinders the U251 human glioma cell growth in vivo via inhibition of angiogenesis with involvement of AKT and FAK dephosphorylation. Salinomycin (0.5 mg/kg b.wt.) enhances the mean survival time of the tumor bearing Swiss albino mice.